Biotest produces several human blood plasma derived concentrates for intensive care medicines. These include Pentaglobin, an IgM enriched immunoglobulin, and other intravenously administered solutions, for the treatment of severe bacterial infections, coagulation disorders, and volume- or protein-substitution.
For the treatment of Haemophilia A and B, Biotest AG manufactures two preparations which derive from human plasma and are designed for intravenous injection.
Biotest produces several antibody concentrates from human blood plasma which are available as ready-to-use solutions. Biotest offers the IVIG preparation Intratect and different hyperimmunoglobulins with increased antibody titers against cytomegaloviruses (CMV), hepatitis B viruses (HBV) or varicella zoster viruses (VZV).
Through its wide range of biological functions, its stability and high solubility, Biotest Human Serum Albumin is suitable for use as a multifunctional excipient for biotechnological, pharmaceutical and diagnostic applications. It is manufactured in a GMP compliant, state-of-the-art facility and complies with the regulatory requirements of multiple health authorities.
02.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.The issuer is solely responsible for the content of this announcement.The EQS Distribution Servi ...
[More]
23.06.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.The issuer is solely responsible for the content of this announcement.The EQS Distribution Servi ...
[More]
Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with effect from 6 June 2025Dreieich, 03 ...
[More]
Announcement according to Article 17 European Market Abuse Regulation (MAR) Change of the Chief Executive Officer (CEO) of Biotest AG Dreieich, 28 May 2025. The Supervisory Board ...
[More]
12.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.The issuer is solely responsible for the content of this announcement.The EQS Distribution Servi ...
[More]
Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest AG: Delisting agreement and announced delisting tender offereieich, March 31, 2025: Biotest AG (ISIN DE0005227201, I ...
[More]
31.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.The issuer is solely responsible for the content of this announcement.The EQS Distribution Servi ...
[More]
Ad hoc NOTICENotification pursuant to Art. 17 EU Market Abuse Regulation (MAR) CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the ...
[More]
27.02.2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ...
[More]
Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest publishes preliminary business figures - 2024 forecasts partially exceededDreieich, 26 February 2025 ...
[More]
09.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.The issuer is solely responsible for the content of this announcement.The EQS Distribution Servi ...
[More]
15.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
14.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR) Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged Dreieich, Germany,&n ...
[More]
29.10.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
02.10.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
12.09.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
05.09.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
28.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
06.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ...
[More]
Investor Relations
Investor Relations
The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.
